WAVE Life Sciences
733 Concord Avenue
About WAVE Life Sciences
WAVE Life Sciences is a preclinical genetic medicine company focused on advancing first-in-class or best-in-class stereopure nucleic acid therapies for patients impacted by rare diseases. We are utilizing our innovative and proprietary synthetic chemistry platform to design and develop nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, with a goal of delivering new and exceptional treatment options for patients. Given the versatility of our chemistry, WAVE’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi, potentially enabling us to address a broad range of therapeutic areas and diseases.
Please click here for clinical trial information.
FOLLOW WAVE LIFE SCIENCES:
Tweets by Wave Life Sciences
67 articles with WAVE Life Sciences
Although the reduction in mHTT with the drug compared to placebo was statistically significant, there was no change in total huntingtin protein (tHTT) compared to placebo.
Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington’s Disease
WVE-120102 demonstrates statistically significant reduction in disease-causing mutant HTT protein in CSF vs. placebo
Wave Life Sciences Announces Discontinuation of Suvodirsen Development for Duchenne Muscular Dystrophy
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced its decision to discontinue development of suvodirsen for patients with Duchenne muscular dystrophy (DMD) who have mutations amenable to exon 51 skipping, based on its interim analysis of the Phase 1 open-label extension (OLE) study.
Wave Life Sciences Ltd., a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced financial results for the third quarter ended September 30, 2019 and provided a business update.
Although a definite blow to Sarepta, this may have negative implications for other companies working to develop therapies for DMD. This includes Wave Life Sciences and Solid Biosciences.
1/29/2019The Massachusetts Biotechnology Council (MassBio) is taking the lead in fostering the next generation of life science leaders in the Bay State with Project Onramp, an internship program that matches talented students from low-income backgrounds with paid internships in the state’s vibrant life sc...
Wave Life Sciences is working to get its nucleic acid treatment, suvodirsen, for Duchenne muscular dystrophy (DMD) approved. DMD is a rare muscle-wasting disease that affects mostly boys, about 15,000 in the U.S.
New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.
Wave Life Sciences Announces Positive Phase 1 Results for WVE-210201 in Duchenne Muscular Dystrophy (DMD)
Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that the safety and tolerability data from the WVE-210201 Phase 1 clinical trial in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping support initiation of a Phase 2/3 clinical trial.
Research will focus on inherited retinal diseases associated with RHO, USH2A, ABCA4 and CEP290
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it has entered into a research, development and commercial collaboration and multi-program option agreement with Wave Life Sciences Ltd.
Preclinical Data Supporting Wave Life Sciences ALS and FTD Programs Presented at 28th International Symposium on ALS/MND
Lead candidate targets C9ORF72; in vivo animal data demonstrate potent, sustained and preferential knockdown of toxic biomarkers associated with ALS and FTD.
Wave reported a net loss of $26.1 million for the third quarter of 2017, as compared to a net loss of $17.5 million for the third quarter of 2016.
This clinical trial marks the next stage in the company’s ongoing commitment to address the significant unmet needs of patients diagnosed with this devastating disease and it is the company’s third clinical trial initiated in 2017.
10/27/2017Wave Life Sciences has officially opened a new state-of-the art manufacturing facility to support advancement of the company’s stereopure nucleic acid platform.
WAVE Life Sciences Announces Publication Of Paper In Nature Biotechnology Establishing The Importance Of Stereochemical Purity In Oligonucleotide Drug Design
WAVE Life Sciences Initiates Two Phase 1b/2a Clinical Trials: PRECISION-HD1 And PRECISION-HD2 In Patients With Huntington’s Disease